LOESTRIN 21 1 Drug Patent Profile
✉ Email this page to a colleague
When do Loestrin 21 1 patents expire, and what generic alternatives are available?
Loestrin 21 1 is a drug marketed by Teva Branded Pharm and is included in two NDAs.
The generic ingredient in LOESTRIN 21 1 is ethinyl estradiol; norethindrone acetate. Twenty-five suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
US Patents and Regulatory Information for LOESTRIN 21 1
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Branded Pharm | LOESTRIN 21 1.5/30 | ethinyl estradiol; norethindrone acetate | TABLET;ORAL-21 | 017875-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Branded Pharm | LOESTRIN 21 1/20 | ethinyl estradiol; norethindrone acetate | TABLET;ORAL-21 | 017876-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
